Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, alleging misleading statements and safety issues at the Grasberg Block Cave mine in Indonesia [2][6]. Group 1: Lawsuit Details - The lawsuit claims that Freeport-McMoRan failed to ensure adequate safety at its Grasberg Block Cave mine, leading to heightened risks for workers [6]. - It is alleged that the company's statements regarding its business operations and prospects were materially false and misleading due to undisclosed risks [6]. - Investors who purchased securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Next Steps for Investors - Investors wishing to join the class action must move the Court by January 12, 2026, to serve as lead plaintiff [4]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [4][7]. - It is noted that no class has been certified yet, and investors are encouraged to select qualified counsel with a successful track record [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [6]. - The defendants are accused of making false statements regarding the reliability and functionality of the G6 and G7 devices, leading to increased regulatory scrutiny and potential financial harm [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Insights - Lycos Energy Inc. reported a significant decline in financial performance for Q3 2025, with total petroleum and natural gas sales decreasing by 43% year-over-year to CAD 19.4 million, and adjusted funds flow from operations down 44% to CAD 9.6 million [2][4][8] - The company has focused on operational efficiency and cost reduction, resulting in a 30% decrease in net operating expenses per barrel of oil equivalent (boe) [8][6] - Following a recent asset divestiture, Lycos plans to return CAD 47.9 million to shareholders as a capital return, amounting to CAD 0.90 per common share [5][7] Financial Performance - Total petroleum and natural gas sales for Q3 2025 were CAD 19,379 thousand, down from CAD 33,986 thousand in Q3 2024, marking a 43% decrease [2] - Adjusted funds flow from operations for Q3 2025 was CAD 9,558 thousand, compared to CAD 17,005 thousand in Q3 2024, a 44% decline [2] - Net income for Q3 2025 was CAD 2,465 thousand, down 33% from CAD 3,706 thousand in the same quarter of the previous year [2] Production and Costs - Average daily production in Q3 2025 was 2,958 boe/d, a 39% decrease from 4,836 boe/d in Q3 2024 [2][8] - The realized price for crude oil was CAD 72.24 per barrel, down 7% from CAD 77.96 per barrel in Q3 2024 [2] - Net operating expenses per boe decreased by 30% to CAD 15.48 in Q3 2025 from CAD 22.08 in Q3 2024 [8] Strategic Initiatives - The company has paused exploration and development activities to prioritize operational efficiency and has implemented initiatives to improve logistics and streamline field execution [6][8] - Following the divestiture of non-core assets, Lycos is focusing on its retained core areas and plans to resume capital activities in January 2026 [7][6] - The company reported an exit net debt of CAD 11.8 million, representing a low ratio of 0.3 times annualized net debt to adjusted funds flow from operations [8][7]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed adverse facts affecting the company's financial performance [2][5]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Molina to contact them regarding their legal options, particularly for those who purchased securities between February 5, 2025, and July 23, 2025 [1][2]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose critical information, including: - Material adverse facts about the company's medical cost trend assumptions [5]. - A dislocation between premium rates and medical costs [5]. - Dependency on low utilization of behavioral health, pharmacy, and inpatient and outpatient services for near-term growth [5]. - Likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. - Misleading positive statements regarding the company's business and prospects [5]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [6]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [6]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting full-year adjusted earnings guidance to no less than $19.00 per diluted share, representing a 13.6% reduction [7][8]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Stride, Inc. for alleged violations of federal securities laws, particularly regarding misleading statements and undisclosed information related to the company's products and services [2][5]. Group 1: Allegations Against Stride, Inc. - The complaint alleges that Stride and its executives made false and misleading statements about their products and services, claiming they were designed to help learners reach their full potential, while in reality, the company was inflating enrollment numbers and cutting staff costs excessively [5]. - A report from Gallup-McKinley County Schools Board of Education accused Stride of fraud and deceptive practices, including retaining "ghost students" to secure state funding and ignoring compliance requirements [6]. - Following these allegations, Stride's stock price dropped by $18.60, or 11.7%, closing at $139.76 per share on September 15, 2025, impacting investors negatively [7]. Group 2: Financial Performance and Impact - On October 28, 2025, Stride reported its first quarter fiscal 2026 results, indicating a deliberate limitation on enrollment growth due to execution improvements and system implementation issues, which led to 10,000 to 15,000 fewer enrollments [8]. - The announcement of these challenges caused Stride's stock price to fall as much as 51% during intraday trading on October 29, 2025, further harming investors [8]. Group 3: Legal Proceedings - Investors who suffered losses during the specified period are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options, with a deadline of January 12, 2026, to seek the role of lead plaintiff in the class action lawsuit [2][10]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Freeport-McMoRan Inc. due to allegations of violations of federal securities laws related to safety issues at the Grasberg Block Cave mine in Indonesia, which resulted in significant investor losses [2][5]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Freeport-McMoRan to contact them directly to discuss their legal rights [1]. - There is a deadline of January 12, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Freeport [2]. - The complaint alleges that Freeport and its executives made false or misleading statements regarding safety at the Grasberg mine, which posed a heightened risk to workers [5]. Group 2: Incident and Stock Price Impact - On September 9, 2025, Freeport suspended mining activities at the Grasberg mine after an incident trapped seven workers, leading to a stock price drop of $2.77, or 5.9%, closing at $43.89 per share [6]. - Following an update on September 24, 2025, revealing two fatalities among the trapped workers, Freeport's stock fell by $7.69, or 17%, to close at $37.67 per share [7]. - Additional news on September 25, 2025, regarding the impact of the production halt on Freeport's relationship with the Indonesian government caused the stock to drop by $2.33, or 6.2%, closing at $35.34 [8][9]. Group 3: Expert Opinions and Class Action Details - An article published on September 28, 2025, suggested that the landslide at the Grasberg mine was preventable, indicating that the risks should have been anticipated [9]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is adequate and typical of class members [9]. - Faruqi & Faruqi encourages anyone with information regarding Freeport's conduct to come forward, including whistleblowers and former employees [10].

Toronto, Ontario--(Newsfile Corp. - November 18, 2025) - Canoe Mining Ventures Corp. (TSXV: CLV) (the "Company") is pleased to announce that, further to its press releases of October 31, 2025 and November 3, 2025, it has completed a non-brokered private placement through the issuance of 11,500,000 units (each, a "Unit") in the capital of the Company at a price of $0.05 per Unit for gross proceeds of $575,000 (the "Offering").Each Unit was comprised of one common share (each, a "Common Share") in the capita ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Allegations Against Telix - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [5]. - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission, Telix's American Depositary Shares (ADSs) fell more than 13% over two trading sessions [6]. - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the FDA, which led to a further decline of over 21% in the price of its ADSs [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Firefly Aerospace Inc. due to allegations of misleading statements and failure to disclose critical information regarding the company's financial performance and operational capabilities [2][5]. Group 1: Company Financial Performance - Firefly Aerospace conducted its IPO on August 7, 2025, selling 19.296 million shares at $45.00 per share [6]. - In its first earnings report as a public company on September 22, 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, for the same quarter in 2024 [7]. - Firefly's revenue for the second quarter of 2025 was $15.55 million, which was below analyst estimates of $17.25 million and represented a 26.2% decrease from the same quarter in 2024 [7]. - The revenue from Firefly's Spacecraft Solutions segment was only $9.2 million, indicating a 49% year-over-year decrease [7]. Group 2: Stock Price Reaction - Following the earnings report, Firefly's stock price fell by $7.58 per share, or 15.31%, closing at $41.94 on September 23, 2025 [8]. - After the disclosure of a failure in the Alpha Flight 7 rocket on September 29, 2025, Firefly's stock price dropped by $7.66 per share, or 20.73%, closing at $29.30 on September 30, 2025 [10]. Group 3: Legal Implications - A federal securities class action has been filed against Firefly, with a deadline of January 12, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Firefly and its executives violated federal securities laws by making false and misleading statements regarding the demand for its Spacecraft Solutions and the operational readiness of its Alpha rocket program [5].

Core Insights - Resverlogix Corp. has appointed Mr. Bradley Glass to its board of directors, bringing extensive legal and business experience to the company [1][3]. Company Overview - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company focused on developing first-in-class therapies for chronic diseases, particularly in the field of epigenetics [4]. - The company is developing a new class of epigenetic therapies aimed at regulating disease-causing gene expression, with a focus on improving patients' lives affected by serious illnesses such as cardiovascular disease [5]. Strategic Partnerships - Resverlogix has partnered with EVERSANA™ to facilitate the rapid commercialization of its lead candidate, apabetalone, for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States [6].